Zura Bio Ltd

Zura Bio Ltd (Nasdaq: ZURA) is a clinical-stage biopharmaceutical company focused on immunology and inflammatory disease that entered the public markets through a completed SPAC business combination. Operating as a post-merger public entity in the life sciences sector, Zura Bio is advancing a pipeline of targeted therapies for autoimmune conditions. The company filed a Form 8-K with the U.S. Securities and Exchange Commission on June 18, 2026, disclosing a current material corporate event. For comprehensive data on ZURA's SPAC transaction history, sponsor details, full SEC filing archive, and real-time deal alerts, sign up for a SpacDesk account at spacdesk.com.